Vivus: into single digits Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vivus: into single digits

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Colby who wrote (218)	4/17/1998 1:12:00 PM
From: BDR	Read Replies (1) of 1016

Colby, I think it was E'lane on the other thread who posted: <Colby seems to be our peaceful go between, for I see he breached the lions den today, at great personal cost, to get some answers. He was sent on his way. > I hope you don't feel that you were attacked for posting here. Glad you are still here. With regard to revenue projections: what do you think the pricing for MUSE will be if it is approved outside the US? $20-$24/dose retail in a relatively wealthy country may fly, but what about elsewhere? And how long do you think Vivus can keep the price where it is in the face of Viagra at $8-9/dose? Caverject dropped 30%+ after the introduction of MUSE.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next